Skip to content

Lexicon Pharmaceuticals LXRX Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Cytokinetics logo
CytokineticsCYTK
Mannkind logo
MannkindMNKD
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
Opko Health logo
Opko HealthOPK
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+262%
Enterprise value$976.73M+209%
P/S14.2×+5.4×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's accrued liabilities, current?
Lexicon Pharmaceuticals (LXRX) reported accrued liabilities, current of $6.9M in Q1 2026.
How has Lexicon Pharmaceuticals's accrued liabilities, current changed year-over-year?
Lexicon Pharmaceuticals's accrued liabilities, current decreased by 46.7% year-over-year, from $12.95M to $6.9M.
What is the long-term trend for Lexicon Pharmaceuticals's accrued liabilities, current?
Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's accrued liabilities, current has grown at a -15.0% compound annual growth rate (CAGR), from $29.69M to $13.19M.